BioCentury
ARTICLE | Clinical News

Galeterone: Phase III discontinued

August 1, 2016 7:00 AM UTC

Tokai discontinued the open-label, international Phase III ARMOR3-SV trial in about 148 treatment-naive metastatic CRPC patients whose tumors express androgen receptor splice variant 7 (AR- V7) after...